
-
MacroGenics NasdaqGS:MGNX MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Location: 9704 Medical Center Drive, Rockville, MD, 20850, United States | Website: https://www.macrogenics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-16.99M
Cash
154.1M
Avg Qtr Burn
-17.41M
Short % of Float
10.98%
Insider Ownership
2.92%
Institutional Own.
87.70%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Approved Quarterly sales | ||
ZYNYZ (Retifanlimab) (anti-PD-1 mAb) Details Solid tumor/s, Cancer, Metastatic merkel cell carcinoma, Skin cancer | Approved Quarterly sales | |
Retifanlimab (anti-PD-1 mAb) Details Solid tumor/s, Non-small cell lung carcinoma, Anal cancer, Lung cancer, Cancer | PDUFA Approval decision | |
Enoblituzumab (anti-B7-H3) Details Prostate cancer | Phase 2 Data readout | |
Lorigerlimab (PD-1 × CTLA-4 bispecific DART® molecule) + docetaxel Details Solid tumor/s, Cancer, Castration-resistant prostate cancer | Phase 2 Data readout | |
Vobramitamab duocarmazine (vobra duo) (MGC018) Details Castration-resistant prostate cancer, Cancer, Solid tumor/s | Phase 2 Update | |
Lorigerlimab monotherapy Details Cancer, Platinum-resistant ovarian cancer | Phase 2 Initiation | |
MGC026 Details Cancer, Solid tumor/s | Phase 1 Data readout | |
MGD024 Details Acute myeloid leukemia, Myelodysplastic syndrome | Phase 1 Data readout | |
Vobramitamab duocarmazine (vobra duo) w/lorigerlimab Details Solid tumor/s, Non-small cell lung carcinoma, Cancer, Triple-negative breast cancer , Head and neck squamous cell carcinoma, Melanoma, Castration-resistant prostate cancer | Failed Discontinued | |
Margetuximab (Fc-engineered, anti-HER2 mAb) Details Gastric cancer, Cancer | Failed Discontinued | |
Flotetuzumab (bispecific CD123 × CD3 DART molecule) Details Cancer, Multiple myeloma, Acute myeloid leukemia | Failed Discontinued | |
Enoblituzumab (anti-B7-H3) Details Head and neck squamous cell carcinoma, Cancer | Failed Discontinued |